Bain Capital Life Sciences Investors, LLC has bought stock on 7 days since Dec 2017
10% owner at Heartflow, Inc., and 9 other companies
SEC CIK 0001703031 · Filings on SEC.gov ↗
Bain Capital Life Sciences Investors, LLC's record
3 months after each buy, from the first price a copier could get.
4 buys since 2017 with 3 months of prices.
Companies
- HTFL Heartflow, Inc.10% owner
- KLRA Kailera Therapeutics, Inc.10% owner
- SLDB Solid Biosciences Inc.10% owner
- OLMA Olema Pharmaceuticals, Inc.10% owner
- KYTX Kyverna Therapeutics, Inc.10% owner
- SWTX Springworks Therapeutics, Inc.10% owner
- ARQT Arcutis Biotherapeutics, Inc.10% owner
- DRNA Dicerna Pharmaceuticals Inc10% owner
- REPL Replimune Group, Inc.10% owner
- MRNS Marinus Pharmaceuticals, Inc.10% owner
Every filing
14 filings since Dec 2017, newest first
Heartflow, Inc.
10% owner
Kailera Therapeutics, Inc.
10% owner
Heartflow, Inc.
10% owner
Solid Biosciences Inc.
10% owner
Olema Pharmaceuticals, Inc.
10% owner
Kyverna Therapeutics, Inc.
10% owner
Springworks Therapeutics, Inc.
10% owner
Springworks Therapeutics, Inc.
10% owner
Arcutis Biotherapeutics, Inc.
10% owner
Dicerna Pharmaceuticals Inc
10% owner
Dicerna Pharmaceuticals Inc
Director and 10% owner
Replimune Group, Inc.
10% owner
Marinus Pharmaceuticals Inc
10% owner
Dicerna Pharmaceuticals Inc
Director and 10% owner
About Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC is a Delaware-incorporated investment firm and a key entity within the Bain Capital Life Sciences platform, focused on life sciences investing.( It recently reported beneficial ownership changes in HeartFlow, Inc. (HTFL), holding a significant 10% stake as a corporate insider, with its business address at 200 Clarendon Street, Boston, MA.(
Bain Capital Life Sciences, on which this Investors entity operates, was founded in 2016, building on Bain Capital's four decades of experience in healthcare and life sciences across private equity, public equity, credit, venture capital, and real estate.( The firm invests globally in biopharmaceutical, medical device, diagnostic, and life science tool companies, targeting inflection capital, growth capital, fallen angels, and larger private equity collaborations, with over $7.4 billion in assets under management as of September 30, 2025.( Its team combines deep industry expertise, clinical insights, and cross-asset investing experience from the broader Bain Capital platform, founded in 1984.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.